CO2017013359A2 - Células madre derivadas de placenta, útiles para restaurar el motor regenerativo, corregir defectos proteómicos y ampliar la vida útil de sujetos envejecidos - Google Patents
Células madre derivadas de placenta, útiles para restaurar el motor regenerativo, corregir defectos proteómicos y ampliar la vida útil de sujetos envejecidosInfo
- Publication number
- CO2017013359A2 CO2017013359A2 CONC2017/0013359A CO2017013359A CO2017013359A2 CO 2017013359 A2 CO2017013359 A2 CO 2017013359A2 CO 2017013359 A CO2017013359 A CO 2017013359A CO 2017013359 A2 CO2017013359 A2 CO 2017013359A2
- Authority
- CO
- Colombia
- Prior art keywords
- stem cells
- subject
- tissue
- pdsc
- over time
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 15
- 230000001172 regenerating effect Effects 0.000 title abstract 2
- 230000007547 defect Effects 0.000 title 1
- 210000002826 placenta Anatomy 0.000 title 1
- 108010026552 Proteome Proteins 0.000 abstract 2
- 230000032683 aging Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 230000003169 placental effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La presente invención se refiere, en parte, al uso de células madre, tales como células madre derivadas de placenta (PDSC), para reducir los efectos del envejecimiento, por ejemplo, restaurar el motor regenerativo y prolongar la vida de los sujetos maduros. Se proporcionan en la presente, por ejemplo, métodos para mantener o aumentar la relación entre el número de células madre y el número de células diferenciadas en un tejido de un sujeto a lo largo del tiempo, que comprenden administrar al sujeto una cantidad efectiva de una población de células madre (p. ej. , PDSC), en donde la relación se mantiene o aumenta con el tiempo en comparación con la relación entre el número de células madre y el número de células diferenciadas en un tejido de un sujeto de control a lo largo del tiempo. Además, se proporcionan métodos para mantener o aumentar el número de células madre en un tejido de un sujeto a lo largo del tiempo, que comprenden administrar al sujeto una cantidad efectiva de una población de células madre (por ejemplo, PDSC), donde el número de células madre en el el tejido del sujeto se mantiene o aumenta con el tiempo en comparación con el número de células madre en el mismo tejido de un sujeto de control. También se proporcionan en este documento métodos para alterar el fenotipo o proteoma de un residente de células madre en envejecimiento en un tejido de un sujeto, que comprende administrar al sujeto una cantidad efectiva de una población de células madre (por ejemplo, PDSC), en donde la cantidad es efectiva para alterar el nicho ambiental de la célula madre envejecida de modo que el fenotipo o proteoma de la célula madre se altere en comparación con el fenotipo de la célula madre residente en el tejido de un sujeto de control.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562167786P | 2015-05-28 | 2015-05-28 | |
PCT/US2016/034773 WO2016191724A1 (en) | 2015-05-28 | 2016-05-27 | Placental-derived stem cells to restore the regenerative engine, correct proteomic defects and extend lifespan |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017013359A2 true CO2017013359A2 (es) | 2018-03-28 |
Family
ID=57393743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0013359A CO2017013359A2 (es) | 2015-05-28 | 2017-12-22 | Células madre derivadas de placenta, útiles para restaurar el motor regenerativo, corregir defectos proteómicos y ampliar la vida útil de sujetos envejecidos |
Country Status (16)
Country | Link |
---|---|
US (1) | US20160346333A1 (es) |
EP (1) | EP3302065A4 (es) |
JP (3) | JP2018520211A (es) |
KR (2) | KR20180019613A (es) |
CN (1) | CN107846903A (es) |
AU (2) | AU2016267672A1 (es) |
BR (1) | BR112017025586A2 (es) |
CA (1) | CA2987064A1 (es) |
CO (1) | CO2017013359A2 (es) |
EA (1) | EA201792602A1 (es) |
IL (1) | IL255920B2 (es) |
MX (1) | MX2017015145A (es) |
NZ (1) | NZ737474A (es) |
SG (1) | SG10201911206PA (es) |
WO (1) | WO2016191724A1 (es) |
ZA (1) | ZA201707905B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018236134A2 (en) * | 2017-06-21 | 2018-12-27 | Korea Research Institute Of Bioscience And Biotechnology | METHOD AND KIT FOR THE DIAGNOSIS OF MUSCLE WEAK RELATED DISEASES USING A BLOOD BIOMARKER |
EP3803415A1 (en) * | 2018-06-04 | 2021-04-14 | Avon Products, Inc. | Protein biomarkers for identifying and treating aging skin and skin conditions |
KR20200055979A (ko) | 2018-11-14 | 2020-05-22 | (주)아모레퍼시픽 | 피부 노화 모델의 제조방법, 그 방법에 의해 제조된 피부 노화 모델 및 그 피부 노화 모델을 이용한 항노화 물질의 스크리닝 방법 |
CN109355393A (zh) * | 2018-12-12 | 2019-02-19 | 武汉凯德维斯生物技术有限公司 | 宫颈小细胞癌相关的hpv整合基因位点及其应用 |
CN109908323A (zh) * | 2019-04-01 | 2019-06-21 | 李胜 | 一种促成人体骨髓干细胞再生和激活休眠干细胞的复方制品制作方法 |
CN110179827A (zh) * | 2019-06-27 | 2019-08-30 | 北京三有利和泽生物科技有限公司 | 牙源性间充质干细胞的应用 |
TWI761837B (zh) * | 2020-05-20 | 2022-04-21 | 國立中央大學 | 通用人類誘導多能性幹細胞及其生成方法 |
CN112129877B (zh) * | 2020-09-24 | 2021-07-20 | 南京医科大学 | 精浆甘露糖-6-磷酸和新蝶呤检测作为特发性男性不育诊断标志物及其应用 |
CN118176292A (zh) * | 2021-10-14 | 2024-06-11 | 北京干细胞与再生医学研究院 | 年轻化非多能性细胞及其制备方法和应用 |
WO2023090901A1 (ko) * | 2021-11-18 | 2023-05-25 | 의료법인 성광의료재단 | 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법 |
WO2024085637A1 (ko) * | 2022-10-18 | 2024-04-25 | 동국대학교 산학협력단 | 혈장 유래 단백질을 포함하는 노화 방지용 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7611500A (en) * | 1999-09-24 | 2001-04-24 | Abt Holding Company | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
KR20190104428A (ko) * | 2005-12-29 | 2019-09-09 | 안트로제네시스 코포레이션 | 태반 줄기 세포 집단 |
CN104099290A (zh) * | 2006-10-23 | 2014-10-15 | 人类起源公司 | 用胎盘细胞群治疗骨缺损的方法和组合物 |
CA2677679A1 (en) * | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
SI2120977T1 (sl) * | 2007-02-12 | 2014-01-31 | Anthrogenesis Coroporation | Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic |
US9962409B2 (en) * | 2007-10-01 | 2018-05-08 | Vestion, Inc. | Therapy using cardiac stem cells and mesenchymal stem cells |
CN101748096B (zh) * | 2008-12-17 | 2013-03-13 | 北京汉氏联合生物技术有限公司 | 亚全能干细胞、其制备方法及其用途 |
ES2358146B1 (es) * | 2009-10-22 | 2012-03-23 | Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla | Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis. |
-
2016
- 2016-05-27 BR BR112017025586A patent/BR112017025586A2/pt not_active Application Discontinuation
- 2016-05-27 WO PCT/US2016/034773 patent/WO2016191724A1/en active Application Filing
- 2016-05-27 IL IL255920A patent/IL255920B2/en unknown
- 2016-05-27 JP JP2018514934A patent/JP2018520211A/ja active Pending
- 2016-05-27 AU AU2016267672A patent/AU2016267672A1/en not_active Abandoned
- 2016-05-27 EA EA201792602A patent/EA201792602A1/ru unknown
- 2016-05-27 SG SG10201911206PA patent/SG10201911206PA/en unknown
- 2016-05-27 MX MX2017015145A patent/MX2017015145A/es unknown
- 2016-05-27 US US15/167,696 patent/US20160346333A1/en not_active Abandoned
- 2016-05-27 KR KR1020177037541A patent/KR20180019613A/ko not_active Application Discontinuation
- 2016-05-27 CA CA2987064A patent/CA2987064A1/en active Pending
- 2016-05-27 CN CN201680044147.8A patent/CN107846903A/zh active Pending
- 2016-05-27 KR KR1020237033507A patent/KR20230145509A/ko not_active Application Discontinuation
- 2016-05-27 EP EP16800824.1A patent/EP3302065A4/en active Pending
- 2016-05-27 NZ NZ737474A patent/NZ737474A/en unknown
-
2017
- 2017-11-21 ZA ZA2017/07905A patent/ZA201707905B/en unknown
- 2017-12-22 CO CONC2017/0013359A patent/CO2017013359A2/es unknown
-
2021
- 2021-05-13 AU AU2021203074A patent/AU2021203074A1/en active Pending
- 2021-07-01 JP JP2021110177A patent/JP2021165289A/ja active Pending
-
2023
- 2023-06-20 JP JP2023100474A patent/JP2023116745A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112017025586A2 (pt) | 2018-08-07 |
IL255920B2 (en) | 2024-05-01 |
WO2016191724A1 (en) | 2016-12-01 |
US20160346333A1 (en) | 2016-12-01 |
JP2023116745A (ja) | 2023-08-22 |
NZ737474A (en) | 2022-11-25 |
CA2987064A1 (en) | 2016-12-01 |
AU2016267672A1 (en) | 2017-12-21 |
CN107846903A (zh) | 2018-03-27 |
ZA201707905B (en) | 2018-11-28 |
SG10201911206PA (en) | 2020-01-30 |
AU2021203074A1 (en) | 2021-06-10 |
IL255920A (en) | 2018-01-31 |
JP2018520211A (ja) | 2018-07-26 |
KR20180019613A (ko) | 2018-02-26 |
KR20230145509A (ko) | 2023-10-17 |
MX2017015145A (es) | 2018-08-01 |
JP2021165289A (ja) | 2021-10-14 |
EA201792602A1 (ru) | 2018-06-29 |
IL255920B1 (en) | 2024-01-01 |
EP3302065A1 (en) | 2018-04-11 |
EP3302065A4 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017013359A2 (es) | Células madre derivadas de placenta, útiles para restaurar el motor regenerativo, corregir defectos proteómicos y ampliar la vida útil de sujetos envejecidos | |
UY37495A (es) | Dinucleótidos cíclicos como agonistas de sting | |
CO2019000395A2 (es) | Genes de mini–distrofina optimizados y casetes de expresión y su uso | |
BR112015020456A2 (pt) | método para operar um veículo automotor eletrificado e meios para a sua implementação | |
ECSP17059343A (es) | ARNi VARIANTE | |
CO2017003319A2 (es) | Electrolito para celda electroquímica recargable | |
CO2017005391A2 (es) | Composiciones de antibiótico | |
CL2020002915A1 (es) | Composiciones para el tratamiento de condiciones de la piel | |
BR112016007577A2 (pt) | estrutura de proteção de bateria | |
CL2017002729A1 (es) | Proteína de unión a rgma y su uso | |
BR112015023987A2 (pt) | creme dental de duas fases | |
AR113134A1 (es) | Arni variante | |
BR112016010191A2 (pt) | matriz de eluição e usos desta | |
AR093569A1 (es) | Tensioactivos pulmonares reconstituidos | |
CL2020003444A1 (es) | Cuerpo conformado basado en óxido de magnesio y carbonato de calcio y método para su preparación | |
CO2020010793A2 (es) | Composiciones de virus adeno-asociado para restaurar la función del gen pah y métodos de uso de las mismas | |
BR112017011946A2 (pt) | disposição de estabilizador | |
BR112018014905A2 (pt) | método para determinar o envelhecimento de um meio de armazenamento eletroquímico | |
DOP2016000079A (es) | Glicoproteinas recombinantes y sus usos | |
ES2514140B1 (es) | Uso del inhibidor de sulfatasas esteroideas STX64 para el tratamiento del envejecimiento | |
BR112014031381B8 (pt) | Material de catodo ativo de alta tensão e seu método de preparação, bateria secundária de lítio, bem como pacote e veículo elétrico que compreendem a dita bateria | |
BR112015003702A2 (pt) | composição adequada para esgotar os folículos ovarianos em mamíferos fêmeas, e, métodos para induzir esgotamento de folículo ovariano em um mamífero fêmea, para reduzir a capacidade reprodutiva de um mamífero, para controlar o tamanho da população de uma população de mamíferos não humanos e para preparar uma composição. | |
AR099753A1 (es) | Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro | |
AR110871A1 (es) | Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas | |
CO2018005176A2 (es) | Procedimiento para la determinación asistida por ordenador de parámetros de un acumulador de energía electroquímico |